When combined, a subjective list of common childhood behaviors (fidgeting, losing things, distractibility, not following ...

The U.S. Food and Drug Administration is revising the labeling of all extended-release attention-deficit/hyperactivity ...

The U.S. Food and Drug Administration said on Monday it is revising the labeling of all extended-release stimulants used to ...

Labels of all extended-release stimulants indicated for ADHD -- including certain formulations of amphetamine and ...

Agency will require a Limitation of Use section in the prescribing information of all extended-release ADHD stimulants ...

DELAWARE, DE, UNITED STATES, July 4, 2025 /EINPresswire.com/ -- The global Attention Deficit Hyperactivity Disorder (ADHD) market is anticipated to reach USD 18.3 billion by 2025, as a result of ...

Collegium's new ADHD drugs may allow the company to grow revenues faster and pay off debt faster. Click here to find out why ...

Telehealth prescribing of stimulants for teens and adults with ADHD is not linked to a higher risk for substance use disorder vs in-person prescribing, a new study shows.

The US Food and Drug Administration (FDA) is revising the labeling of all extended-release stimulants indicated to treat attention-deficit/hyperactivity disorder (ADHD)—including certain formulations ...

The U.S. Food and Drug Administration said on Monday it is revising the labeling of all extended-release stimulants to treat ...

Children younger than 6 years of age who are prescribed extended-release stimulants for attention-deficit hyperactivity disorder (ADHD) may experience ...